November 06, 2020
06/11/2020
November 06, 2020
JUPITER, FL A new strategy for treating a variety of diseases known as RNA-repeat expansion disorders, which affect millions of people, has shown promise in proof-of-principle tests conducted by scientists at Scripps Research.
The results suggest that someday, a handful of well-targeted drugs might be able to treat the more than 40 human disorders including Huntington's disease and variants of amyotrophic lateral sclerosis (ALS) that arise from RNA-repeat expansions.
This study lays a foundation for the development of drugs that can address multiple repeat-expansion diseases by targeting shared abnormal structures on their RNAs, says the study's principal investigator Matthew Disney, PhD, professor of chemistry at Scripps Research.
In RNA-repeat expansion diseases, mutant genes contain excess DNA in the form of dozens or even hundreds of repeating short strings of DNA letters. In cells where these mutant genes are active, that DNA is copied out into RNA molecules on the way to being translated into proteins. The resulting abnormal RNAs can cause trouble in a variety of ways, such as by folding up into structures that are toxic to cells.
In the study, published in Cell Chemical Biology, the scientists showed that a potential drug molecule they developed can neutralize the toxic RNA that causes two distinct repeat-expansion disorders, myotonic dystrophy 1 (DM1) and Fuchs endothelial corneal dystrophy (FECD). In the latter case, it can do so by an unexpected but powerful mechanism.
Genetic diseases in dire need of a treatment
DM1 is estimated to affect about 140,000 people in the United States. It can manifest anywhere from infancy to adulthood. And while it doesn't always shorten lifespan, it often brings a debilitating set of symptoms including muscle weakness and pain, cataracts, and respiratory and gastrointestinal problems. The disorder is caused by a mutant copy of a gene called DMPK, whose RNAs contain dozens to hundreds of repeats of the RNA letters CUG.
FECD, which causes progressive damage to the cornea of the eye that often necessitates corneal transplantation, has a relatively high prevalence; studies suggest it manifests in at least several percent of Caucasian people older than 50. The disorder is caused by a mutant version of a gene called TCF4, whose RNAs also contain abnormally long CUG repeats.
These disorders arise from different mutant genes, and consequently appear in different cell types, but involve virtually the same toxic mechanism: In each case, the inclusion of an abnormally long sequence of CUG repeats causes the RNA copied from the gene to form structures that are sticky to certain other proteins in the cell, and effectively capture them preventing them from doing their jobs in the cell. The depletion of one of these captured proteins, MBNL1, is a particularly important cause of cell damage and symptoms in DM1 and FECD.
Encouraging results in pre-clinical tests
For the new study, Disney and his team used advanced computational methods to design a small organic molecule that selectively binds to the abnormal CUG-expansion RNAs found in MD1- and FECD-affected cells, preventing these RNAs from capturing MBNL1.
To evaluate and improve the molecule, the team used a unique tool they had developed previously, Competitive Chem-CLIP, which allowed them to test their molecule's ability to selectively recognize toxic CUG-expansion structures.
The team showed that in cultured cells derived from patients with DM1, as well as in an animal model of the disease, their improved designer molecule successfully reduced the depletion of MBNL1 and the loss of its function.
In FECD cells, the drug molecule also worked to prevent signs of disease, but this time by a different and potentially more powerful mechanism. In FECD cells, the disease-causing gene mutation occurs in a non-coding part of the gene called an intron. Normally, introns when copied into RNA are cut out of the RNA almost immediately and degraded by disposal systems in the cell. In FECD, the presence of the CUG-repeat expansion prevents the affected intron from being excised. However, Disney and his team found that their molecule allows that excision to take place, so that the abnormal RNA element is not just blocked but destroyed.
Targeting toxic RNAs with small organic molecules that can be put into pill form has generally been very challenging, so far, Disney notes, but the finding in this study points to the promising possibility of using such molecules not just to block bad RNAs but to trigger their destruction.
If a drug causes a toxic RNA to be destroyed instead of merely blocking it, then the effect should be longer lasting, he says.
Having performed their proof-of-principle demonstration, he and his team, which includes a startup biotech company, Expansion Therapeutics, are continuing to develop the molecule tested in the study as a potential drug treatment for DM1 and FECD.
The researchers also are taking a similar approach in developing potential drug treatments for RNA repeat-expansion diseases involving CAG repeats, which include the progressive and fatal neurological disorder known as Huntington's disease.
Disney notes that his group's computational approach to drug discovery, versus traditional methods involving the screening of large sets, or libraries, of molecules, gives them a big advantage: Our ability to do computation-aided design allows us to get initial compounds quickly, and quickly test them, Disney says.
In addition to Disney, authors of A Small Molecule that Binds an RNA Re
LINK: | https://www.scripps.edu/news-and-events/press-room/2020/20201106-disne... |
See more stories from scripps |
More from Scripps
12/04/2024
April 11, 2024
Scripps Research chemists devise easier new method for making a common type of building block for drugs Scientists transform simple linear amines into saturated...
06/04/2024
April 05, 2024
A simple, inexpensive way to make carbon atoms bind together A Scripps Research team uncovers a cost-effective method for producing quaternary carbon molecules,...
04/04/2024
April 03, 2024
Developing a vaccine for the zombie drug xylazine Scripps Research chemical biologists design an early proof-of-concept vaccine that could lead to the first...
30/03/2024
March 29, 2024
How blocking a neural receptor responsible for addiction could reduce alcohol use A Scripps Research team found that a new therapeutic that targets the kappa op...
13/03/2024
March 13, 2024
New computational strategy boosts the ability of drug designers to target proteins inside the membrane Customized-design approach could streamline the design of...
29/02/2024
February 29, 2024
Scripps Research scientists reveal how first cells could have formed on Earth New phospholipid discovery brings researchers closer to understanding how primordi...
29/02/2024
February 28, 2024
How molecular handedness emerged in early biology Scripps Research chemists fill a major gap in origin-of-life theories. February 28, 2024 LA JOLLA, CA Mole...
22/02/2024
February 21, 2024
Snaking toward a universal antivenom Scripps Research scientists discovered antibodies that protect against a host of lethal snake venoms. February 21, 2024 ...
06/02/2024
February 06, 2024
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases AbbVie...
26/01/2024
January 25, 2024
Re-energizing mitochondria to treat Alzheimer's disease Scripps Research team restored neuron-to-neuron connections in human cells. January 25, 2024 LA JO...
24/01/2024
January 04, 2024
100 years of Science Changing Life: Scripps Research celebrates a century of transforming human health For the last century, institute leaders and renowned scie...
23/01/2024
January 23, 2024
New technology lets researchers track brain cells' off switches The method could shed light on what goes awry in numerous brain conditions when neurons ar...
09/01/2024
January 08, 2024
Three decades of giving: Announcing the Calibr-Skaggs Institute for Innovative Medicines The ALSAM Foundation, founded by the Skaggs family, provides lasting g...
04/01/2024
January 03, 2024
Life science entrepreneur Gene Lay joins Scripps Research Board of Directors Lay, founder of the global biotech company BioLegend, brings invaluable experience ...
21/12/2023
December 20, 2023
Taming a plant-derived toxin Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments. ...
19/12/2023
December 18, 2023
Scripps Research Executive Vice President Eric Topol gives TED talk on transformative power of AI in medicine Topol provides an overview of how AI models can i...
13/12/2023
December 12, 2023
New AI-powered algorithm could better assess people's risk of common heart condition Early detection of atrial fibrillation can reduce the risk of stroke an...
07/12/2023
December 06, 2023
Nanoparticle flu vaccine design shows promise in early tests Scripps Research-designed vaccine could provide broad, enduring protection against influenza A str...
16/11/2023
November 15, 2023
Numerous Scripps Research scientists named Highly Cited Researchers Clarivate's annual, global list represents researchers who have demonstrated significant...
07/11/2023
November 06, 2023
Multiple sclerosis drug invented at Scripps Research slows long-term devastating disease progression Late-breaking data reinforces the effectiveness and safety ...
05/10/2023
October 04, 2023
Keren Lasker named a 2023 Moore Inventor Fellow The prestigious award will support Lasker's inventive research in membraneless organelles and their applica...
22/09/2023
September 21, 2023
Michael Bollong named a 2023 Amgen Young Investigator The prestigious award will support Bollong's research identifying new molecular targets and therapeuti...
09/09/2023
September 08, 2023
Philip Dawson receives 2024 American Chemical Society National Award Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational c...
07/09/2023
September 06, 2023
Scripps Research chemists devise a method for C-H activation of alcohols The method represents a new toolkit for making drugs and other compounds. September 06...
31/08/2023
August 30, 2023
Scripps Research receives $1.5M to surveil infectious disease threats in wastewater Bill & Melinda Gates Foundation award to support the development of multi-pa...
16/08/2023
August 16, 2023
How cold temperatures trigger the brain to boost appetite Scripps Research scientists' discovery could lead to new weight loss and metabolic health treatmen...
08/08/2023
August 07, 2023
Human antibody that targets carfentanil, fentanyl and related opioids reverses overdose effects in preclinical study Scripps Research-developed antibody therapy...
04/08/2023
August 03, 2023
How sensory neurons impact the gut Scripps Research scientists show that the receptor PIEZO2 in sensory neurons controls gut motility and transit time, which a...
26/07/2023
July 26, 2023
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets The expanded strategic collaboration will advan...
23/07/2023
July 21, 2023
Scripps Research scientists develop AI-based tracking and early-warning system for viral pandemics Machine-learning system effectively predicts emergence of pro...
19/07/2023
July 19, 2023
Monitoring T cells may allow prevention of type 1 diabetes Scripps Research study shows that analyzing T cells in blood samples could be used to select at-risk ...
19/07/2023
July 18, 2023
Scripps Research mourns passing of leading organic chemist Albert Eschenmoser Eschenmoser pioneered key reactions in synthetic chemistry and shaped the understa...
15/06/2023
June 14, 2023
Scripps Research awarded $46.8 million by NIH to promote human health through innovative translational science and training The Translational Institute is harne...
13/06/2023
June 13, 2023
Scripps Research's Danielle Grotjahn named 2023 Pew Scholar in the Biomedical Sciences The award will support Grotjahn's study of how cells assemble the...
31/05/2023
May 31, 2023
Crossing the ring: new method enables C-H activation across saturated carbocycles Scripps Research chemists add another powerful tool to their molecular editin...
24/05/2023
May 23, 2023
Scripps Research develops behind-the-scenes tool for better biomedical data discovery The new resource makes datasets more discoverable for life science communi...
19/05/2023
May 15, 2023
Scripps Research neuroscientist Hollis Cline elected to American Academy of Arts and Sciences Cline is recognized for her discoveries about the role of sensory ...
19/05/2023
May 18, 2023
Scripps Research's Skaggs Graduate School awards doctoral degrees to 31st graduating class Commencement ceremony will be livestreamed via Zoom and on instit...
13/05/2023
May 12, 2023
A better route to benzocyclobutenes, sought-after building blocks for drugs Scripps Research chemists devise a new, C-H activation-based method for the synthesi...
09/05/2023
May 08, 2023
Renowned Scripps Research professor Jeffery Kelly elected to National Academy of Sciences Kelly's groundbreaking work on protein misfolding has led to thera...
28/04/2023
April 27, 2023
Mirror-image molecules pave new path for cancer drug discovery By comparing how mirror image versions of small molecules impact clusters of proteins, Scripps R...
22/04/2023
April 21, 2023
How alcohol consumption contributes to chronic pain A Scripps Research team showed how both alcohol intake and alcohol withdrawal can lead to increased pain and...
21/04/2023
April 20, 2023
Xin Jin receives dual awards to study autism risk genes in neurodevelopment Major grants from the National Institutes of Health and California Institute for Reg...
20/04/2023
April 19, 2023
Trim the sugar: New HIV vaccine design improves immune response Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA A...
18/04/2023
April 17, 2023
Therapeutic can seek and destroy potent opioid to treat overdoses Scripps Research chemists developed a new biologic to work against the synthetic opioid carfen...
07/03/2023
March 06, 2023
How heavy alcohol consumption increases brain inflammation The findings by a Scripps Research team point toward a potential new drug target for treating alcohol...
02/03/2023
March 01, 2023
Scientists find human antibodies that can block multiple coronaviruses including SARS-CoV-2 Results from a Scripps Research and UNC team pave the way for a vacc...
28/02/2023
February 28, 2023
$10 million grant funds Scripps Research Alcohol Research Center through its 50th year The five-year grant supports research into the neurobiology of alcohol us...
28/02/2023
February 27, 2023
Immune system drug shows promise in treating alcohol use disorder, a Scripps Research clinical trial reports Scientists at Scripps Research found that apremilas...
23/02/2023
February 16, 2023
Chemically poisoned protein acts as a molecular switch to spur cancer formation The discovery triggered development of a new potential drug to eliminate tumor...